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Objectives: To compare outcomes of children receiving noninvasive 
ventilation with those receiving invasive ventilation as first-line mode of 
mechanical ventilation following unplanned intensive care admission.
Design: Propensity score-matched cohort study analyzing data 
prospectively collected by the Pediatric Intensive Care Audit Net-
work over 8 years (2007–2014).
Setting: Thirty-one PICUs in the United Kingdom and Ireland; 
twenty-one of whom submitted Pediatric Critical Care Minimum 
Dataset data for the entire study period.
Patients: Children consecutively admitted to study PICUs. Planned 
admissions following surgery, unplanned admissions from other hos-
pitals, those on chronic ventilation, and those who did not receive 
mechanical ventilation on the day of PICU admission were excluded.
Interventions: Use of noninvasive ventilation, rather than invasive 
ventilation, as the first-line mode of mechanical ventilation.
Measurements and Main Results: PICU mortality, length of ventila-
tion, length of PICU stay, and ventilator-free days at day 28. During 
the study period, there were 151,128 PICU admissions. A total of 
15,144 admissions (10%) were eligible for analysis once predefined 
exclusion criteria were applied: 4,804 (31.7%) received “noninvasive 
ventilation first,” whereas 10,221 (67.5%) received “invasive ventila-
tion first”; 119 (0.8%) admissions could not be classified. Admitting 
PICU site explained 6.5% of the variation in first-line mechanical ven-
tilation group (95% CI, 2.0–19.0%). In propensity score-matched 
analyses, receiving noninvasive ventilation first was associated with 
a significant reduction in mortality by 3.1% (95% CI, 1.7–4.6%), 
length of ventilation by 1.6 days (95% CI, 1.0–2.3), and length of 
PICU stay by 2.1 days (95% CI, 1.3–3.0), as well as an increase in 
ventilator-free days at day 28 by 3.7 days (95% CI, 3.1–4.3).
Conclusions: Use of noninvasive ventilation as first-line mode of 
mechanical ventilation in critically ill children admitted to PICU in an 
unplanned fashion may be associated with significant clinical ben-
efits. Further high-quality evidence regarding optimal patient selec-
tion and timing of initiation of noninvasive ventilation could lead to 
less variability in clinical care between institutions and improved 
patient outcomes. (Crit Care Med 2017; 45:1045–1053)
Key Words: invasive ventilation; mortality; noninvasive ventilation; 
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Invasive ventilation (IV), delivered through an endotra-cheal tube, has long been the mainstay of ventilator man-agement in PICU worldwide (1). Randomized controlled 
trials (RCTs) in adults with chronic obstructive pulmonary 
disease and cardiogenic pulmonary edema, and in premature 
newborns with respiratory distress, have demonstrated that 
noninvasive ventilation (NIV) modalities such as continu-
ous or bi-level positive airway pressure can reduce the need for 
endotracheal intubation and improve patient outcomes (2–6). 
However, there is a paucity of RCT evidence in critically ill 
children: just one clinical trial including only 50 patients, and 
three other small RCTs restricted to specific conditions such 
as bronchiolitis, asthma, and dengue shock syndrome exist 
(7–10). Despite this scarcity of evidence, national audit data from 
PICUs in the United Kingdom and Ireland have shown increasing 
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use of NIV over the past 10 years (11), mirroring an international 
trend of greater adoption of NIV (12, 13).
The main benefits of NIV are that it may avoid several of the 
inherent risks associated with intubation such as upper airway 
trauma, postextubation vocal cord dysfunction, requirement 
for heavy sedation, and ventilator-associated complications 
such as pneumonia, barotrauma, or volutrauma to the lung 
(14, 15). On the other hand, a delay in intubation in a deterio-
rating patient on NIV itself appears to be an independent risk 
factor for mortality (16, 17). As such, the decision of whether 
to use NIV or IV as the first-line mode of mechanical venti-
lation (MV) is currently left to the discretion of the treating 
clinician. Although the choice of NIV or IV may be clear-cut in 
some patient groups, there is little evidence as to which mode 
of ventilation produces the most favorable outcomes in the 
majority of the remaining cases.
In the absence of RCT evidence confirming whether IV 
or NIV is the best initial mode of ventilation in the acute set-
ting, we aimed to perform propensity score matching (PSM) 
analysis using a large observational dataset to compare patient 
outcomes for these two groups. PSM is a powerful, statisti-
cal, matching approach that allows the creation of quasi-
randomized trial conditions to facilitate direct comparison of 
treatment groups (18, 19) and has produced results that are 
generally consistent with RCT findings across a diverse range 
of critical care topics (20–25).
METHODS
We performed a PSM cohort study utilizing prospectively col-
lected data from the Pediatric Intensive Care Audit Network 
(PICANet) clinical audit database. A core admission dataset 
has been collected by PICANet on every admission to U.K. 
and Ireland PICUs since January 2004, containing clinical and 
demographic data (26, 27). An additional dataset, the Pediatric 
Critical Care Minimum Dataset (PCCMDS), has been collected 
for most PICUs since January 2007, on daily interventions for 
each patient. Data quality is ensured by regular training of staff, 
and with local and central validation checks (28). PICANet has 
approval to collect personally identifiable data under special cir-
cumstances from the Health Research Authority Confidentiality 
Advisory Group (ref: PIAG 4–07(c)/2002) and approval from the 
Trent Medical Research Ethics Committee (ref: 05/MRE04/17).
Data
Our intention was to study only those patients who theoretically 
could have received either NIV or IV as first-line therapy at PICU 
admission. Therefore, we extracted data only for children (< 16 
yr old) admitted to PICU during the 8-year period, January 2007 
to December 2014, who received either NIV and/or IV on the 
calendar day of PICU admission, and applied a series of exclu-
sion criteria to restrict the sample (Fig. 1). Postoperative admis-
sions, elective admissions, and emergency admissions from 
another hospital were excluded due to the greater likelihood of 
IV during surgery, for elective procedures, or during transport, 
which may have led to bias in the exposure status. Additionally, 
patients with a tracheostomy on admission and those receiving 
chronic ventilation prior to PICU admission were excluded. 
All remaining individuals were then classified into one of three 
groups, based on which type of ventilation they received first: 
“NIV-first,” “IV-first,” or “unable to classify.” In cases where both 
types of MV were recorded on the calendar day of PICU admis-
sion, we checked MV status on the next calendar day; if only IV 
was recorded on the next calendar day, patients were classified 
as NIV-first, and if only NIV was recorded on the next calendar 
day, patients were classified as IV-first.
Outcomes
The outcome variables were PICU mortality, length of venti-
lation (LOV), PICU length of stay (LOS), and ventilator-free 
days at 28 days (VFD-28). Participants’ VFD-28 was calculated 
as 28-X, where X was the number of days spent receiving MV. 
Patients requiring MV for greater than or equal to 28 days 
Figure 1. Flowchart detailing sample selection criteria. aIt was not 
possible to classify patients who received both noninvasive ventilation 
(NIV) and invasive ventilation (IV) on the day of admission, as well as the 
subsequent day, according to Paediatric Critical Care Minimum Dataset 
(PCCMDS) daily data.
Copyright © 2017 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Pediatric Critical Care
Critical Care Medicine www.ccmjournal.org 1047
and those who died within 28 days of PICU admission were 
assigned a VFD-28 of zero (29). We performed a subgroup 
analysis to study outcomes in NIV-first children who failed 
NIV. “NIV failure” was defined as receiving IV the same or sub-
sequent day of last receiving NIV.
Statistical Analysis
Analysis 1: Whole Cohort. Patient Characteristics Associated 
With Use of NIV as First-Line Treatment. Descriptive statistics 
were calculated to explore differences between MV groups. Mul-
tilevel logistic regression analysis was carried out to investigate 
patient characteristics associated with the choice of first-line MV 
modality, as well as to quantify the effect of PICU site on choice 
of MV modality. Since Pediatric Index of Mortality (PIM)-2, 
the Severity of Illness Score used in U.K. PICUs, is calculated 
using a number of physiologic variables, including if the child is 
receiving MV within the first hour of PICU admission (30), the 
individual elements of the score (excluding the variable related 
to MV) were used rather than the calculated PIM-2 score. The 
multilevel model was created using backward elimination of 
covariates, and the model with the lowest Akaike’s Information 
Criteria value chosen as the final model (31).
Analysis 1: Whole Cohort. Association Between MV 
Modality and Patient Outcome. All outcome variables were 
initially investigated for differences between MV modalities 
across the whole cohort.
Analysis 1: Whole Cohort. Propensity Score (PS) Estimates. 
Several PS estimates were then created, and covariate bias 
was compared between estimates, to find the estimates that 
removed systematic differences in the covariate bias between 
NIV-first and IV-first patients (32).
Analysis 2a: PSM Sample.  The primary analysis was PSM, 
which used nearest-neighbor matching of the logit of the PS 
using caliper widths equal to 0.2 of the pooled sd of the logit 
of the PS, not allowing replacement. The “PS” is defined as 
the probability of treatment group assignment conditional on 
observed baseline covariates (18, 19). Therefore, this meant 
only one IV case could be matched with each NIV case, who 
theoretically had an equal chance of receiving NIV or IV based 
on key characteristics (19, 33). The PSM analysis compared 
patients receiving NIV-first with IV-first (baseline group) 
across all outcomes.
Analysis 2b: Regression Adjustment (RA) Sample. Addi-
tionally, we performed RA using the PS and assigned treatment 
group (18, 34). This method allows a regression model to be 
specified. Logistic regression was used to investigate mortality, 
whereas Poisson regression was used to investigate LOV, LOS, 
and VFDs. RA was carried out on all patients with a calculated 
PS to allow comparison with other study findings and to retain 
a larger sample size. Participants “excluded” from PSM with-
out a match in the opposing treatment group were therefore 
included in the RA sample.
Power Analysis. Sample size calculations indicated that a 
total sample of 4,650 participants (3,100 IV and 1,550 NIV) 
would be sufficient to detect a significant increase in mortal-
ity by 2%, an increase in mean LOV and LOS by 1 day, and 
a decrease in mean VFD-28 by 1 day in IV-first compared to 
NIV-first patients with 90% power. This sample size assumes 
a ratio of two IV admissions to one NIV admission and uses 
previous mean outcome statistics for NIV and IV patients (35).
RESULTS
PICANet data were available on 151,128 consecutive admis-
sions to 31 PICUs between January 2007 and December 2014. 
Twenty-one of these PICUs submitted data across the whole 
8-year period. The remaining 10 varied from submitting 1 year 
of data (two PICUs) to 7 years of data (three PICUs). A total 
of 15,144 admissions (10%) met the study inclusion criteria 
(Fig. 1).
Patients
It was possible to classify 99.2% of admissions in the restricted 
sample into one of the two groups: NIV-first or IV-first. NIV was 
used as the first-line therapy in 4,804 patients (32%), whereas 
10,221 patients (68%) received IV-first. Those admissions that 
could not be classified (119/15,144; 0.8%) were not analyzed 
further. Cohort demographics are described in Table 1.
Analysis 1: Whole Cohort (n = 15,025)
Patient Characteristics Associated With Choice of First-Line 
MV Modality. Patient characteristics were significantly dif-
ferent between the MV groups. In particular, IV-first patients 
had a significantly higher admission severity of illness (median 
PIM-2 score, 5.1% vs 2.8%), serum lactate (median, 1.9 vs 
1.6), and were more likely to have an arterial Pao
2
/Fio
2
 value 
recorded (42.1% vs 16.8%) compared to NIV-first patients 
(Table 1). In those patients who did have a Pao
2
/Fio
2
 ratio 
recorded, NIV-first patients had a lower Pao
2
/Fio
2
 value than 
IV-first patients.
Multilevel logistic regression revealed that PICU site 
explained 6.5% of the variation in first-line MV group (95% 
CI, 2.0–19.0%). The care area admitted from, primary diag-
nostic group, systolic blood pressure (SBP), base excess 
(BE), BE polarity (positive or negative), and Pao
2
/Fio
2
 ratio 
measured within 1 hour of PICU admission were all associ-
ated with choice of MV modality (Supplemental Table 1, 
Supplemental Digital Content 1, http://links.lww.com/CCM/
C531). Receiver operating characteristic (ROC) analysis cal-
culated the area under the ROC curve for this model in pre-
dicting use of IV-first to be 0.85 (95% CI, 0.83–0.88), for the 
1,657 patients with values for all of the covariates included in 
the model.
Comparing Outcomes for NIV-First and IV-First Admis-
sions. Crude mortality rate was significantly lower in patients 
receiving NIV-first (Table 2) compared to patients who 
received IV-first (4.4% vs 9.6%; chi-square test p < 0.001). 
LOV was also significantly different between NIV-first and IV-
first patients (median [interquartile range (IQR)], 4 [2–7] vs 4 
[2–7]; p < 0.001), as well as LOS (median [IQR], 5 [2–9] vs 5 
[3–8]; p < 0.001). Patients receiving NIV-first also had signifi-
cantly greater VFD-28 than those patients receiving IV-first 
(median [IQR], 12 [0–22] vs 8 [0–24]; p = 0.016). The NIV 
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TABLE 1. Patient Demographic and Clinical Characteristics of the Whole Cohort (n = 
15,025) and Propensity Score-Matched Cohort (n = 6,002)
Characteristics
Whole Cohort (n = 15,025) Propensity Score Matching Cohort (n = 6,002)
Invasive Ventila-
tion
(n = 10,221)
Noninvasive 
Ventilation
(n = 4,804) p
Invasive Venti-
lation
(n = 3,001)
Noninvasive 
Ventilation
(n = 3,001) p
Age in weeks, median (IQR) 66 (12–279) 27 (7–144.5) < 0.001 33 (8–162) 28 (7–174) 0.444
Sex, n (%)       
 Male 5,945 (58.1) 2,698 (56.2) 0.032 1,698 (56.6) 1,709 (57.0) 0.774
Primary diagnostic group, n (%)       
 Respiratory 3,292 (32.2) 3,427 (71.3) < 0.001 1,857 (61.9) 1,853 (61.8) 0.993
 Cardiovascular 1,496 (14.6) 409 (8.5)  395 (13.2) 374 (12.5)  
 Neurologic 2,217 (21.7) 182 (3.8)  141 (4.7) 148 (4.9)  
 Infection 904 (8.8) 296 (6.2)  211 (7.0) 221 (7.4)  
 Gastrointestinal 306 (3.0) 63 (1.3)  51 (1.7) 54 (1.8)  
 Endocrine/metabolic 333 (3.3) 72 (1.5)  56 (1.9) 60 (2.0)  
 Trauma 669 (6.6) 4 (0.1)  2 (0.1) 3 (0.1)  
 Oncology 167 (1.6) 70 (1.5)  58 (1.9) 65 (2.2)  
 Blood/lymphatic 149 (1.5) 68 (1.4)  54 (1.8) 56 (1.9)  
 Othera 643 (6.3) 177 (3.7)  155 (5.2) 144 (4.8)  
 Not recorded 45 (0.4) 36 (0.7)  21 (0.7) 23 (0.8)  
Main reason for admission,b n (%)
 Asthma 186 (1.8) 115 (2.4) < 0.001 68 (2.3) 70 (2.3)  
 Bronchiolitis 935 (9.2) 1,502 (31.5)  619 (20.6) 607 (20.2) 0.969
 Croup 108 (1.1) 16 (0.3)  15 (0.5) 15 (0.5)  
 Obstructive sleep apnea 12 (0.1) 35 (0.7)  11 (0.4) 8 (0.3)  
 Diabetic ketoacidosis 13 (0.1) 2 (0.1)  3 (0.1) 2 (0.1)  
 Seizure disorder 78 (0.8) 5 (0.1)  3 (0.1) 5 (0.2)  
 Other (none of the above) 8,804 (86.1) 3,099 (64.3)  2,282 (76.0) 2,294 (76.4)  
 Not recorded 84 (0.8) 30 (0.6)  0 0  
Ethnicity,c n (%)       
 White 6,175 (60.4) 2,678 (55.7) < 0.001 1,719 (57.3) 1,760 (58.7) 0.842
 Mixed White 333 (3.3) 166 (3.5)  105 (3.5) 113 (3.8)  
 Asian 1,297 (12.7) 732 (15.3)  478 (15.9) 449 (15.0)  
 Black 550 (5.4) 314 (6.5)  205 (6.8) 197 (6.6)  
 Other 1,592 (15.6) 800 (16.7)  422 (14.0) 409 (13.6)  
 Not recorded 272 (2.6) 112 (2.3)  72 (2.4) 73 (2.4)  
(Continued)
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Care area admitted from, n (%)       
 Ward 4,117 (40.3) 2,891 (60.2) < 0.001 1,775 (59.2) 1,769 (58.9) 0.544
 X-ray 261 (2.6) 7 (0.1)  8 (0.3) 5 (0.2)  
 High dependency unit 1,095 (10.7) 542 (11.3)  432 (14.4) 419 (14.0)  
 Other intermediate care area 137 (1.3) 96 (2.0)  35 (1.2) 48 (1.6)  
 ICU/PICU/neonatal ICU 152 (1.5) 36 (0.8)  30 (1.0) 23 (0.8)  
 Emergency department 4,436 (43.4) 1,210 (25.2)  721 (24.0) 737 (24.6)  
 Unknown 12 (0.1) 10 (0.2)  0 0  
 Not recorded 11 (0.1) 12 (0.2)  0 0  
Admission year, n (%)       
 2007 433 (4.2) 195 (4.1) < 0.001 125 (4.2) 127 (4.2) 0.940
 2008 1,054 (10.3) 414 (8.6)  259 (8.6) 264 (8.8)  
 2009 1,215 (11.9) 411 (8.6)  317 (10.6) 301 (10.0)  
 2010 1,334 (13.0) 543 (11.3)  364 (12.1) 358 (11.9)  
 2011 1,372 (13.4) 611 (12.7)  379 (12.6) 413 (13.8)  
 2012 1,562 (15.3) 847 (17.6)  530 (17.7) 513 (17.1)  
 2013 1,605 (15.7) 942 (19.6)  529 (17.6) 533 (17.8)  
 2014 1,646 (16.1) 841 (17.5)  498 (16.6) 492 (16.4)  
Distribution of admissions to  
each PICUd
NA NA < 0.001 NA NA 0.486
Pediatric Index of Mortality- 
2–predicted probability of  
death (%), median (IQR)
5.1 (3.1–10.7) 2.8 (0.9–5.4) < 0.001 4.5 (1.9–9.2) 4.0 (1.3–7.1) < 0.001
Arterial or capillary blood gas 
taken,b n (%)
      
 Yes 7,588 (74.2) 2,925 (60.9) < 0.001 2,093 (69.7) 2,133 (71.1) 0.258
Lactate,b median (IQR) 1.9 (1.1–3.7) 1.6 (1.1–2.6) < 0.001 1.8 (1.0–3.5) 1.6 (1.1–2.6) 0.014
Not recorded, n (%) 6,798 (66.5) 3,347 (69.7)  64.9 65.4  
Pao2/Fio2 ratio,
b median (IQR) 190.6 (102.6–354.6) 129.4 (85.7–200) < 0.001 150 (86–258) 129 (84–202) < 0.001
Not recorded, n (%) 5,923 (57.9) 3,998 (83.2)  64.7 78.2  
Base excess,b median (IQR) –3.1 (–7.0 to 0.3) 1.0 (–2.0 to 4.8) < 0.001 –1.4 (–5.3 to 2.1) 0.9 (–2.3 to 4.9) < 0.001
Not recorded, n (%) 3,201 (31.3) 2,186 (45.5)  1,035 (34.5) 1,080 (36.0)  
Age-standardized systolic blood 
pressureb z score, mean (sd)
–0.03 (1.18) 0.13 (0.98) < 0.001 0.061 (1.02) 0.089 (1.02) 0.288
IQR = interquartile range, NA = not applicable.
a The “other” category included in primary diagnostic group also contains patients with the primary diagnostic groups: body wall and cavities, multisystem and 
musculoskeletal, all of which represent < 1% of the population each.
b Variables measured within 1 hr of admission and used to derive Pediatric Index of Mortality-2–predicted probability of death.
c The variable “ethnicity” has been transformed into six broad groups from the original 18 groups collected by Pediatric Intensive Care Audit Network.
d Number of noninvasive ventilation and invasive ventilation admissions per unit not displayed due to large number of units.
A Wilcoxon rank-sum test was used to compare all continuous variables presented as mean (interquartile range), a two sample t test was used to compare 
continuous variables presented as mean (sd), and chi-square test of independence compared all categorical variables presented as n (%).
TABLE 1. (Continued). Patient Demographic and Clinical Characteristics of the Whole 
Cohort (n = 15,025) and Propensity Score-Matched Cohort (n = 6,002)
Characteristics
Whole Cohort (n = 15,025) Propensity Score Matching Cohort (n = 6,002)
Invasive Ventila-
tion
(n = 10,221)
Noninvasive 
Ventilation
(n = 4,804) p
Invasive Venti-
lation
(n = 3,001)
Noninvasive 
Ventilation
(n = 3,001) p
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failure rate of those receiving NIV-first was 25.7% (1,237 admis-
sions). The crude outcomes for those participants who failed 
NIV compared to those who succeeded on NIV were mortality 
of 10.2% versus 2.1% (p < 0.001), median LOV of 8 (IQR, 5–14) 
versus 3 (IQR, 2–5) (p < 0.001), median LOS of 9 (IQR, 6–16) 
versus 4 (IQR, 3–6) (p < 0.001), and median VFD-28 of 0 (IQR, 
0–0) versus 16 (IQR, 0–22) (p < 0.001). The median VFD-28 of 
NIV failure admissions remained when patients who had died 
within 28 days of admission were excluded.
LOV, LOS, and VFD-28 were significantly different in those 
patients who failed NIV compared to those patients receiving 
IV-first (p < 0.001). However, there was no difference in mor-
tality (p = 0.503).
PS Estimates. PS estimates were created for 13,189 patients, 
who had recorded values for all of the matching variables 
(3,900 NIV and 9,289 IV). The final PSs adjusted for admitting 
PICU, primary diagnostic group, presence of a low-risk PIM-2 
diagnosis, ethnicity, whether a blood gas (arterial or capillary) 
was measured within 1 hour of admission, the care area from 
which the child was admitted, age-standardized SBP z score, 
admission year, age, and sex. Of these 13,189 patients, 899 
NIV-first patients did not have an IV-first match, and 6,288 
IV-first patients did not have an NIV-first match, within the 
specified caliper distance. The NIV-first and IV-first patients 
thus excluded from the PSM analysis had significantly differ-
ent PICU mortality rates (2.1% vs 9.8%; p < 0.001). Figure 
2 illustrates the distribution of 
PSs by MV modality.
Analysis 2a: PSM Sample 
(n = 6,002)
The PSM analysis used 6,002 
children (3,001 NIV and 3,001 
IV). Their characteristics and 
crude outcomes are compared 
in Tables 1 and 2, and dem-
onstrate that PSM matching 
produced comparable groups 
in terms of baseline variables. 
PSM analysis summarized in 
Table 3 found that receiving 
NIV-first was associated with 
a significant decrease in mor-
tality by 3.1% (95% CI, 1.7–
4.6%) to 5.4% compared to 
8.5% in IV-first patients. LOV 
decreased by 1.6 days (95% CI, 
1.0–2.3) from 8.4 to 6.8 days, 
and there was an associated 
decrease in LOS by 2.1 days 
TABLE 2. Crude Outcomes for Patients Included in the Whole Cohort (n = 15,025) and 
Propensity Score-Matched Cohort (n = 6,002)
Outcome
Whole Cohort (n = 15,025) Propensity Score Matching Cohort (n = 6,002)
Invasive Ven-
tilation
(n = 10,221)
NIV
(n = 4,804) p
Invasive 
Ventilation
(n = 3,001)
NIV
(n = 3,001) p
PICU mortality (%) 9.6 4.4 < 0.001 8.5 5.9 < 0.001
Length of ventilation (d), median (IQR) 4 (2–7) 4 (2–7) < 0.001 5 (3–9) 4 (2–7) < 0.001
Length of stay (d), median (IQR) 5 (2–9) 5 (3–8) < 0.001 6 (4–11) 5 (3–9) < 0.001
VFD-28—all patients, median (IQR) 8 (0–24) 12 (0–22) 0.016 0 (0–16) 8 (0–22) < 0.001
VFD-28—survivors only, median (IQR) 12 (0–24) 12 (0–22) 0.269 0 (0–16) 12 (0–22) < 0.001
NIV failure rate, n (%) NA 1,237 (25.7) NA NA 948 (33.3) NA
IQR = interquartile range, NA = not applicable, NIV = noninvasive ventilation, VFD-28 = ventilation-free days at day 28.
A Wilcoxon rank-sum test was used to compare all continuous variables presented as mean (interquartile range), a two sample t test was used to compare 
continuous variables presented as mean (sd), and chi-square test of independence compared all categorical variables presented as n (%).
Figure 2. Distribution of the calculated propensity scores for noninvasive ventilation (NIV)-first and invasive 
ventilation (IV)-first patients, with or without a match (n = 13,189).
Copyright © 2017 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.
Pediatric Critical Care
Critical Care Medicine www.ccmjournal.org 1051
(95% CI, 1.3–3.0) from 10.7 to 8.6 days in NIV-first patients. 
Use of NIV-first was associated with an increase in VFD-28 by 
3.7 days (95% CI, 3.1–4.3) to 10.8 days compared to 7.1 days 
in IV-first patients.
Analysis 2b: RA Sample  
(n = 13,189)
Similar results were obtained from the RA using the full sam-
ple of 13,189 patients in whom PSs were calculated. The use of 
NIV-first was associated with a significant decrease in mortal-
ity by 1.6% (95% CI, 0.3–3.0), a decrease in LOV by 0.1 days 
(95% CI, –0.6 to 0.4) and LOS by 0.3 days (95% CI, –1.1 to 
0.5), and a significant increase in VFD-28 by 1.6 days (95% CI, 
1.1–2.1) (Table 3).
In both PSM and RA, a significant increase in VFD-28 of 
NIV-first remained when patients who had died within 28 days 
of admission were excluded. In PSM, a significant increase in 
VFD-28 by 3.6 days was reported (95% CI, 3.0–4.2), whereas 
RA found a significant increase of 1.5 days (95% CI, 0.9–2.0) 
using the sample of 13,189 patients.
DISCUSSION
In this large study of critically ill children admitted to U.K. PICUs, 
we have identified several important clinical factors associated 
with the use of NIV as the first-line mode of MV. As well as signifi-
cant inter-unit variability in the use of NIV, PSM analysis suggests 
that receiving NIV-first is associated with a significant reduction 
in mortality, LOV, LOS, and a significant increase in VFD-28. We 
recognize that these findings are only applicable to those patients 
for whom NIV is a clinically appropriate first-line option.
To our knowledge, this is the first study to compare the ben-
efits of NIV versus IV as first-line treatment in a large cohort 
of critically ill children. While not an RCT, the use of PSM to 
analyze a national high-quality, observational dataset cover-
ing an 8-year period allows our findings to be generalized to 
other similar developed healthcare systems. Additionally, PSM 
analysis comparing NIV and IV in adult ICU patients reported 
findings consistent with RCTs conducted on the same topic 
(20–25). In our study, when the unmatched cohorts were com-
pared, IV-first patients were considerably sicker at admission 
and had worse outcomes. PSM allowed the two groups to be 
well matched across a range of key covariates, with better out-
comes seen in patients treated with NIV-first.
Characteristics that influenced the choice of first-line MV type 
in our study are consistent with previous studies, which identified 
differences between NIV and IV patients in terms of illness sever-
ity, the ratio of oxygen saturation to Fio
2
 (Spo
2
/Fio
2
), age, sex, 
whether a blood gas was taken (36–39), and variability between 
hospitals in the use of NIV in critically ill children (39). In our 
study, admitting PICU explained 6.5% of the variation in NIV or 
IV use, although the upper CI reached 19.0%. Our findings show 
that patients admitted to PICU in a more severe clinical status are 
more likely to receive IV so as not to delay intubation. Similarly, 
the presence of acute respiratory distress syndrome, indicated by 
a Pao
2
/Fio
2
 ratio of less than 200, has been previously shown to be 
a strong risk factor for NIV failure (40, 41).
Several previous small observational studies support our find-
ings of patient benefit with the use of NIV. In a study comparing 
two distinct 5-year epochs in one PICU, Essouri et al (42) showed 
that LOV and PICU LOS decreased significantly when NIV was 
introduced as the main mode of MV in children with acute bron-
chiolitis. Similarly, a comparison of two units (one delivering IV 
only and the other predominantly NIV) showed that the LOV 
for infants with bronchiolitis was significantly shorter with NIV 
use (36). A retrospective analysis of bronchiolitis admissions at a 
single center in Australia over a 10-year period showed that PICU 
LOS was nearly halved with the use of NIV (43). Similar data 
have been reported for acute asthma (39). However, not all stud-
ies adjusted for confounding factors, and the lack of multicenter 
involvement prevents widespread generalizability of their find-
ings. Findings from the few RCTs available on this topic in criti-
cally ill children do support the premise of improved outcomes 
for selected patients treated with NIV in preference to IV (7–10).
TABLE 3. Results of Analyses Comparing Patients Receiving Noninvasive Ventilation First 
With the Control Group (Invasive Ventilation First), Across Four Patient Outcomes, Using 
Both Propensity Score Matching (n = 6,002) and Regression Adjustment (n = 13,189)
Outcome
Average Treatment Effect Coefficient for Noninvasive Ventilation First
Propensity Score Matching Using 
Nearest Neighbor Matching
(n = 6,002) 95% CI
Regression Adjustment
(n = 13,189) 95% CI
PICU mortality (%) –3.1 –4.6 to –1.7 –1.6a –3.0 to –0.3
Length of ventilation (d) –1.6 –2.3 to –1.0 –0.1b –0.6 to 0.4
Length of stay (d) –2.1 –3.0 to –1.3 –0.3b –1.1 to 0.5
VFD-28—all patients 3.7 3.1–4.3 1.6b 1.1–2.1
VFD-28—survivors only 3.6 3.0–4.2 1.5b 0.9–2.0
VFD-28 = ventilation-free days at day 28.
a Calculated using logistic regression adjustment.
b Calculated using Poisson regression adjustment.
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Our sample included data on almost all PICU admissions 
in the United Kingdom and Ireland, and therefore had suffi-
cient power to detect clinically significant differences across all 
four outcomes. Furthermore, by excluding patients in whom 
PICU clinicians could not choose the first-line MV mode 
(planned admissions, unplanned admissions from other hos-
pitals, patients on chronic ventilation, and those with a trache-
ostomy), we focused on those patients in whom our findings 
can be applied in the future. Several limitations of this study 
must also be noted: PSM can only match on measured vari-
ables and therefore cannot eliminate all potential confounding 
bias. PSM also reduced the sample to a smaller subset of the 
overall cohort, restricting the generalizability of our findings. 
Selection bias may be present as only 21 of 31 PICUs submitted 
PCCMDS data for the entire 8-year study period, and although 
PICANet stipulated that high-flow therapy should be classified 
as “supplemental oxygen,” some units may have miscoded it as 
NIV. Potential confounding bias may have arisen from vari-
ables with multiple unrecorded values. This was particularly 
evident with the Pao
2
/Fio
2
 ratio (missing in 83% of NIV-first 
patients). The unexpectedly lower value in the NIV-first group 
may be explained by the fact that only sicker patients were 
likely to have arterial catheters in this group. It was not appro-
priate to use multiple imputation to predict unrecorded values, 
as these values were not missing at random.
In addition, the study did not address other research ques-
tions such as complications of NIV use, nor does it clarify the 
reasons behind significant inter-unit variability or allow our 
findings to be easily generalized to postoperative patients or 
transported admissions.
CONCLUSIONS
The use of acute NIV (rather than IV) as first-line MV ther-
apy may be associated with a significant decrease in mortality, 
LOV, and LOS, as well as an increase in the number of VFD-28. 
Admitting PICU has a strong association with which type of MV 
is used first. Variation in the use of NIV and IV between PICUs 
may therefore directly influence clinical outcomes. Prospective 
clinical trials conducted through international collaborative 
networks and research-driven clinical guidelines are urgently 
needed to guide future NIV practice in critically ill children.
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